Study guide

4.2 Diagnostic Testing, Screening & Predictive Values

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

4.2 Diagnostic Testing, Screening & Predictive Values

Key Takeaways Explain This Topic AI

Sensitivity (TP / [TP + FN]) and specificity (TN / [TN + FP]) represent intrinsic diagnostic properties that remain constant regardless of disease prevalence in an identical clinical population.

Positive predictive value (PPV) and negative predictive value (NPV) depend heavily on disease prevalence; when prevalence drops, PPV decreases sharply and NPV approaches 100%.

Positive likelihood ratio (Sensitivity / [1 - Specificity]) > 10 provides decisive ruling-in utility, whereas negative likelihood ratio ([1 - Sensitivity] / Specificity) < 0.1 provides decisive ruling-out utility.

Lowering a biomarker diagnostic threshold increases sensitivity and negative predictive value while reducing specificity and positive predictive value.

Wilson and Jungner screening criteria require a well-defined condition, a recognizable latent stage, an acceptable and validated test, and an agreed management policy.

Last updated: September 2026

Note

Curriculum Focus : The MRCP(UK) Part 1 frequently tests mathematical calculations based on 2x2 contingency tables. Candidates are expected to rapidly compute sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and positive/negative likelihood ratios (LR+ and LR-), as well as interpret the clinical consequences of altering diagnostic cut-off points on ROC curves.

Diagnostic tests do not provide absolute diagnostic certainty; instead, they alter the clinical probability that a condition is present. Evidence-based diagnostic decision-making relies on applying Bayesian principles to convert pre-test probability into post-test probability.

The Core 2x2 Contingency Table

All fundamental diagnostic metrics are derived from a standard 2x2 table comparing the index test result against the reference ('gold standard') diagnosis:

  • Index Test Result Reference Standard: Disease Present Reference Standard: Disease Absent Marginal Total
  • Test Positive (+) True Positive (TP) [a] False Positive (FP) [b] Total Test Positive (a + b)
  • Test Negative (-) False Negative (FN) [c] True Negative (TN) [d] Total Test Negative (c + d)
  • Marginal Total Total Diseased (a + c) Total Non-Diseased (b + d) Total Population (a + b + c + d)
  • Intrinsic Test Parameters: Sensitivity and Specificity

Sensitivity and specificity describe the performance of a test against an established reference standard. They are intrinsic biological properties of the test; assuming the diagnostic threshold and clinical spectrum remain constant, they do not change when the disease prevalence changes.

1. Sensitivity (True Positive Rate)

Formula :

Sensitivity = True Positives / Total Diseased = a / (a + c)

Clinical Meaning : The probability that a patient with the disease tests positive.

Clinical Mnemonic : SnNOut — A test with high Sn (Sensitivity), when N (Negative), rules Out the disease. A highly sensitive test generates very few false negatives (FN). Example: D-dimer in low-probability pulmonary embolism; high sensitivity ensures a negative result safely excludes PE.

False Negative Rate (FNR) : The proportion of diseased individuals missed by the test:

  • False Negative Rate = 1 - Sensitivity = c / (a + c)
  • 2. Specificity (True Negative Rate)

Formula :

Specificity = True Negatives / Total Non-Diseased = d / (b + d)

Clinical Meaning : The probability that a patient without the disease tests negative.

Clinical Mnemonic : SpPIn — A test with high Sp (Specificity), when P (Positive), rules In the disease. A highly specific test generates very few false positives (FP). Example: Anti-dsDNA antibodies in systemic lupus erythematosus; high specificity confirms SLE.

False Positive Rate (FPR) : The proportion of healthy individuals falsely flagged as diseased:

  • False Positive Rate = 1 - Specificity = b / (b + d)
  • Predictive Values and Prevalence Dependence

Unlike sensitivity and specificity, predictive values reflect clinical practice directly: "Given my patient's positive or negative test result, what is the probability that they actually have the condition?"

Predictive Value Formulas

Positive Predictive Value (PPV) :

PPV = True Positives / Total Test Positives = a / (a + b)

Negative Predictive Value (NPV) :

  • NPV = True Negatives / Total Test Negatives = d / (c + d)
  • Impact of Disease Prevalence (Bayes' Theorem in Practice)

Predictive values are heavily dependent on disease prevalence in the tested cohort: +------------------------------------------------------------------------------------------+

  • | Impact of Changing Disease Prevalence |
  • +------------------------------------------------------------------------------------------+
  • | Disease Prevalence INCREASES: |
  • | • Positive Predictive Value (PPV) INCREASES |
  • | • Negative Predictive Value (NPV) DECREASES |
  • | |
  • | Disease Prevalence DECREASES (e.g., General Population Screening): |
  • | • Positive Predictive Value (PPV) PLUMMETS (Most positive tests are False Positives!) |
  • | • Negative Predictive Value (NPV) APPROACHES 100% |
  • +------------------------------------------------------------------------------------------+
  • Worked Example: The Screening Paradox

Consider an assay with 90% sensitivity and 95% specificity applied to two different populations of 10,000 individuals:

High-Prevalence Clinic Cohort (Prevalence = 20%) :

  • Diseased: 2,000 patients | Healthy: 8,000 patients
  • True Positives = 2,000 x 0.90 = 1,800
  • False Positives = 8,000 x (1 - 0.95) = 400
  • PPV = 1,800 / (1,800 + 400) = 1,800 / 2,200 = 81.8%

Low-Prevalence Population Screening (Prevalence = 1%) :

  • Diseased: 100 patients | Healthy: 9,900 patients
  • True Positives = 100 x 0.90 = 90
  • False Positives = 9,900 x 0.05 = 495
  • PPV = 90 / (90 + 495) = 90 / 585 = 15.4%

Important

MRCP Exam Trap : In the low-prevalence screening setting, despite an excellent 95% specificity, nearly 85% of all positive test results are false positives . This is the fundamental reason unselected screening for rare disorders is discouraged.

Likelihood Ratios and the Fagan Nomogram

Likelihood ratios (LRs) combine sensitivity and specificity into a single metric that quantifies how much a given test result raises or lowers the odds of disease. Crucially, likelihood ratios are independent of disease prevalence .

Mathematical Definitions

Positive Likelihood Ratio (LR+) :

LR+ = Sensitivity / (1 - Specificity) = True Positive Rate / False Positive Rate

Describes the odds of a positive test in a diseased patient compared to a non-diseased patient.

Negative Likelihood Ratio (LR-) :

LR- = (1 - Sensitivity) / Specificity = False Negative Rate / True Negative Rate

Describes the odds of a negative test in a diseased patient compared to a non-diseased patient.

Clinical Interpretation Benchmarks

  • Likelihood Ratio Shift in Post-Test Probability Clinical Diagnostic Impact
  • LR+ > 10 Increases probability by > 45% Conclusive ruling-in utility ; often diagnostic in isolation
  • LR+ 5.0 – 10.0 Increases probability by 30% – 45% Moderate ruling-in utility; substantially alters management
  • LR+ 2.0 – 5.0 Increases probability by 15% – 30% Small shift; useful when combined with other findings
  • LR+ 1.0 – 2.0 Increases probability by < 15% Minimal shift; rarely clinically decisive
  • LR = 1.0 0% shift Completely uninformative test (post-test = pre-test)
  • LR- 0.5 – 1.0 Decreases probability by < 15% Minimal ruling-out utility
  • LR- 0.2 – 0.5 Decreases probability by 15% – 30% Moderate ruling-out utility
  • LR- 0.1 – 0.2 Decreases probability by 30% – 45% Substantial ruling-out utility
  • LR- < 0.1 Decreases probability by > 45% Conclusive ruling-out utility ; safely excludes condition
  • Bayesian Odds Calculations and Fagan Nomogram

To convert probabilities using likelihood ratios:

  • Convert Pre-test Probability (P) to Pre-test Odds: Odds = P / (1 - P)
  • Calculate Post-test Odds: Post-test Odds = Pre-test Odds x Likelihood Ratio
  • Convert Post-test Odds back to Post-test Probability: Probability = Odds / (Odds + 1)

In the clinic, a Fagan Nomogram bypasses calculation: aligning a straight ruler connecting Pre-test Probability on the left vertical axis through the calculated Likelihood Ratio on the central vertical axis allows direct reading of Post-test Probability on the right axis.

Receiver Operating Characteristic (ROC) Curves

When a diagnostic test yields a continuous numerical variable (e.g., serum troponin, PSA, ferritin), clinicians must select a cut-off threshold to designate results as 'positive' or 'negative'. An ROC curve visualizes the trade-off across all potential cut-off values. True Positive Rate (Sensitivity)

  • 1.0 +---------------------------------*
  • | * |
  • | * |
  • 0.8 | * |
  • | * |
  • 0.6 | * |
  • | * |
  • 0.4 | * | Diagonal line: AUC = 0.5
  • | * | (Chance discrimination)
  • 0.2 | * |
  • | * |
  • 0.0 +---------------------------------+
  • 0.0 0.2 0.4 0.6 0.8 1.0
  • False Positive Rate (1 - Specificity)
  • Core Properties of the ROC Curve

Axes : The vertical y-axis plots Sensitivity (True Positive Rate). The horizontal x-axis plots 1 - Specificity (False Positive Rate).

Area Under the Curve (AUC / c-statistic) :

AUC = 1.0 : Perfect discrimination (100% sensitivity with 100% specificity).

AUC = 0.5 : Discrimination no better than random chance (represented by the 45-degree diagonal reference line).

AUC 0.70 – 0.79 : Acceptable discriminatory accuracy.

AUC 0.80 – 0.89 : Excellent discriminatory accuracy.

AUC >= 0.90 : Outstanding clinical accuracy.

Youden's Index (J) : The mathematical point on the ROC curve maximizing overall classification efficiency:

J = Sensitivity + Specificity - 1

Graphically, it represents the point on the ROC curve with the greatest vertical distance from the diagonal line of chance.

Clinical Consequences of Adjusting the Cut-off Threshold

Cut-Off Adjustment Sensitivity Specificity False Negatives False Positives Clinical Application

Lowering Cut-off (e.g., Troponin from 14 to 5 ng/L) Increases Decreases Decreases Increases Emergency screening / Rule-out : Where missing a disease is fatal (ACS, pulmonary embolism, neonatal metabolic screens).

Raising Cut-off (e.g., Ferritin for haemochromatosis) Decreases Increases Increases Decreases Confirmation / Rule-in : Prior to invasive, toxic, or irreversible therapies (chemotherapy, surgical resection).

Wilson and Jungner Screening Criteria

Screening identifies asymptomatic disease in a population. The UK National Screening Committee (UK NSC) bases national screening policy (e.g., breast cancer mammography, diabetic retinopathy, bowel cancer FIT testing, abdominal aortic aneurysm ultrasound) on the classic Wilson and Jungner (WHO) criteria :

The Condition : Must be an important health problem with a recognized latent or early asymptomatic phase, and its natural history must be well understood.

The Test : Must be simple, safe, validated, reliable, acceptable to the target population, with an established and agreed cut-off level.

The Treatment : There must be an accepted, effective intervention available for patients identified with the disease, and initiating therapy during the latent phase must yield better clinical outcomes than waiting for symptoms to emerge.

The Healthcare System : Adequate facilities for definitive diagnosis and treatment must be available; there must be an agreed policy on whom to treat; and the financial cost of case-finding must be economically balanced relative to total medical expenditure.

Loading diagram... Bayesian Probability & Diagnostic Decision Framework